Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year

1990

Stage

Series B | Dead

Total Raised

$6.8M

Last Raised

$3.6M

About Dallas Biomedical

Developing biopharmaceutical products based on proprietary technologies centered on the vascular system. The company has utilized these technologies to develop cancer diagnostics and therapeutics. Two drugs, an immunosuppressor dipeptide and IMTOX22, are currently in phase I clinical trials. The immunosuppressor dipeptides are used as a bone marrow purging agent to prevent rejection after marrow transplants, especially in donors who are not perfect genetic matches. IMTOX22 is used as an antibody-targeted toxin to selectively destroy B cells in patients with B-cell lymphoma. Two additional therapeutics have shown promising results in preclinical trials. One is a vascular targeting technology to treat malignant tumors by destroying the capillaries supplying nutrients required for tumor growth. The second therapeutic combines antibody targeting and magnetic resonance imaging (MRI) to develop antibody-targeted MRI agents. These antibody-targeted MRI agents are highly sensitive, providing high resolution without radiation.

Dallas Biomedical Headquarter Location

14457 Gillis Road

Dallas, Texas, 75244,

United States

(214)450-3897

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.